This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sunshine Act Survey: More Than 50% Of Physicians Unprepared

PORTSMOUTH, N.H., Feb. 4, 2013 /PRNewswire/ -- MMIS' third annual survey of doctors and their knowledge of the Sunshine Act found that physicians are actually less informed than they were one year ago. With the release of the final rules implementing the Sunshine Act on February 1, 2013, consumers and interested parties will have access to a comprehensive and searchable database to review certain payments and transfers of value made by pharmaceutical and medical device manufacturers to physicians and teaching hospitals. This healthcare policy is intended to increase transparency on the relationships between physicians and pharmaceutical and medical device companies.

The survey revealed that of the more than 1,000 physician respondents, over half admitted they didn't know that the law requires pharmaceutical and medical device companies to report on expenditures annually, and that such information would be available in a publicly searchable database.  63% were deeply concerned that a record of these payments will be available in a publicly searchable database.

Additional survey findings disclose that 21% of physicians would sever their relationship with a manufacturer who reported inaccurate information about payments or transfers of value if disclosed to the public, and 43% admitted this would affect their ongoing relationship with industry. The survey also included written physician comments and concerns; these ranged from loss of privacy to a lack of awareness on the part of the general public as to the context of physician/industry relationships.

This lack of understanding is increasingly problematic as the law's implementation date draws closer. This year's survey results reflect a 5% increase in unfamiliarity with the law's provisions by doctors in all types of care locations, from teaching hospitals to private practices.

"There are approximately 3,000 manufacturers of drugs and devices providing valuable education and resources to physicians that enhance patient care. Increasing transparency of the relationship between industry and our healthcare providers will undoubtedly encourage scrutiny by the public, physician peers and their institutions," said CEO of MMIS, Michaeline Daboul. "Government, industry and physician organizations will need to increase communication in this new age of transparency, share data prior to public dissemination and provide a process for physicians and institutions to resolve disputes regarding incorrect or inaccurate information."

According to the survey, 54% of physicians who had industry relationships received samples, 57% received food or beverages in the workplace, 48% participated in a medical industry sponsored program, 11% participated in speaker bureau programs, 10% participated in advisory board programs and most surprisingly, 2% are still accepting free event tickets or gifts.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs